A215600 Stock Overview
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SillaJen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,685.00 |
| 52 Week High | ₩7,260.00 |
| 52 Week Low | ₩3,950.00 |
| Beta | 0.56 |
| 1 Month Change | -6.86% |
| 3 Month Change | -11.44% |
| 1 Year Change | -25.40% |
| 3 Year Change | n/a |
| 5 Year Change | -91.89% |
| Change since IPO | -63.54% |
Recent News & Updates
Shareholder Returns
| A215600 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.6% | 2.4% | 0.6% |
| 1Y | -25.4% | 11.1% | 6.9% |
Return vs Industry: A215600 underperformed the KR Biotechs industry which returned 11.1% over the past year.
Return vs Market: A215600 underperformed the KR Market which returned 6.9% over the past year.
Price Volatility
| A215600 volatility | |
|---|---|
| A215600 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A215600 has not had significant price volatility in the past 3 months.
Volatility Over Time: A215600's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 42 | Eun-Sang Moon | www.sillajen.com |
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine.
SillaJen, Inc. Fundamentals Summary
| A215600 fundamental statistics | |
|---|---|
| Market cap | ₩481.58b |
| Earnings (TTM) | -₩20.37b |
| Revenue (TTM) | ₩3.94b |
122.2x
P/S Ratio-23.6x
P/E RatioIs A215600 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A215600 income statement (TTM) | |
|---|---|
| Revenue | ₩3.94b |
| Cost of Revenue | ₩2.48b |
| Gross Profit | ₩1.46b |
| Other Expenses | ₩21.83b |
| Earnings | -₩20.37b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -198.16 |
| Gross Margin | 36.98% |
| Net Profit Margin | -517.04% |
| Debt/Equity Ratio | 14.2% |
How did A215600 perform over the long term?
See historical performance and comparison